Abstract

Several clinical and scientific factors have made therapeutic innovation in ovarian cancer challenging. An asymptomatic early-stage presentation makes screening for the disease difficult. As a result, 70% of patients are diagnosed with advanced stage disease. In addition, the heterogeneity of tumour subtypes in ovarian cancer poses considerable scientific challenge to its treatment.

Keywords: Shots-on-goal; Cancer-specific portfolio; Benefits of diversification; Mega fund; Economic value; Calibrated correlations;